Mostrar el registro sencillo del ítem

dc.contributor.author
Crispo, James  
dc.contributor.author
Fortin, Yannick  
dc.contributor.author
Thibault, Dylan P.  
dc.contributor.author
Emons, Matthew  
dc.contributor.author
Bjerre, Lise M.  
dc.contributor.author
Kohen, Dafna E.  
dc.contributor.author
Pérez Lloret, Santiago  
dc.contributor.author
Mattison, Donald  
dc.contributor.author
Willis, Allison W.  
dc.contributor.author
Krewski, Daniel  
dc.date.available
2018-03-14T20:18:43Z  
dc.date.issued
2015-08  
dc.identifier.citation
Crispo, James; Fortin, Yannick; Thibault, Dylan P.; Emons, Matthew; Bjerre, Lise M.; et al.; Trends in inpatient antiparkinson drug use in the USA, 2001-2012; Springer; European Journal Of Clinical Pharmacology; 71; 8; 8-2015; 1011-1019  
dc.identifier.issn
0031-6970  
dc.identifier.uri
http://hdl.handle.net/11336/38806  
dc.description.abstract
Purpose: Although therapeutic options and clinical guidelines for Parkinson's disease (PD) have changed significantly in the past 15 years, prescribing trends in the USA remain unknown. The purpose of this population-based cohort study was to examine patterns of inpatient antiparkinson drug use between January 2001 and December 2012 in relation to clinical guideline publication, drug introduction/withdrawal, and emerging safety concerns. Methods: A total of 16,785 inpatients receiving pharmacological treatment for PD were identified in the Cerner Health Facts database. Our primary outcome was standardized (age, sex, race, and census region) annual prevalence of antiparkinson drug use. We also examined antiparkinson medication trends and polypharmacy by age and sex. Results: The most frequently prescribed antiparkinson drugs between 2001 and 2012 were levodopa (85 %) and dopamine agonists (28 %). Dopamine agonist use began declining in 2007, from 34 to 27 % in 2012. The decline followed publication of the American Academy of Neurology's practice parameter refuting levodopa toxicity, pergolide withdrawal, and pramipexole label revisions. Despite safety concerns for cognitive impairment and falls, individuals = 80 years of age demonstrated stable rates of dopamine agonist use from 2001 to 2012. Polypharmacy was most common in younger patients. Conclusions: Dopamine agonist use declined from 2007 to 2012, suggesting that increased awareness of safety issues and practice guidelines influenced prescribing. These events appear to have minimally influenced treatment provided to older PD patients. Antiparkinson prescribing trends indicate that safety and best practice information may be communicated effectively.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Springer  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
Cohort Study  
dc.subject
Drug Utilization  
dc.subject
Medical Records  
dc.subject
Parkinson'S Disease  
dc.subject
Pharmacoepidemiology  
dc.subject.classification
Medicina Critica y de Emergencia  
dc.subject.classification
Medicina Clínica  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
Trends in inpatient antiparkinson drug use in the USA, 2001-2012  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2018-03-13T13:59:00Z  
dc.journal.volume
71  
dc.journal.number
8  
dc.journal.pagination
1011-1019  
dc.journal.pais
Alemania  
dc.journal.ciudad
Berlin  
dc.description.fil
Fil: Crispo, James. University of Ottawa; Canadá. University of Pennsylvania; Estados Unidos  
dc.description.fil
Fil: Fortin, Yannick. University of Ottawa; Canadá  
dc.description.fil
Fil: Thibault, Dylan P.. University of Pennsylvania; Estados Unidos  
dc.description.fil
Fil: Emons, Matthew. Cerner Corporation; Estados Unidos  
dc.description.fil
Fil: Bjerre, Lise M.. University of Ottawa; Canadá. Bruyère Research Institute; Canadá  
dc.description.fil
Fil: Kohen, Dafna E.. University of Ottawa; Canadá  
dc.description.fil
Fil: Pérez Lloret, Santiago. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina  
dc.description.fil
Fil: Mattison, Donald. Risk Sciences International; Canadá. University of Ottawa; Canadá  
dc.description.fil
Fil: Willis, Allison W.. University of Pennsylvania; Estados Unidos  
dc.description.fil
Fil: Krewski, Daniel. University of Ottawa; Canadá  
dc.journal.title
European Journal Of Clinical Pharmacology  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://link.springer.com/article/10.1007/s00228-015-1881-4  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1007/s00228-015-1881-4